Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1113.80% is 43% below its 1-year average of -776.75%, near the low end of its 1-year range (-1578.17%–0.00%).
44.54% below its 12-month average of -770.58%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -352.15%.
EBITDA MARGIN
-1113.80%
EBITDA MARGIN AVG TTM
-770.58%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-44.54%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$62.78M
EBITDA Margin
-0.14%
TTM Avg
-3.20%
3Y Avg
-62.68%
5Y Avg
-125.61%
Market Cap
$63.78M
EBITDA Margin
-11538.23%
TTM Avg
-6406.80%
3Y Avg
-3544.47%
5Y Avg
-2835.62%
Market Cap
$64.18M
EBITDA Margin
-46.36%
TTM Avg
-44.45%
3Y Avg
-49.00%
5Y Avg
-37.18%
Market Cap
$60.42M
EBITDA Margin
-99843.01%
TTM Avg
-70984.01%
3Y Avg
-70984.01%
5Y Avg
-70984.01%
Market Cap
$60.02M
EBITDA Margin
-753.96%
TTM Avg
-753.96%
3Y Avg
-753.96%
5Y Avg
-753.96%
Market Cap
$65.85M
EBITDA Margin
-794.91%
TTM Avg
-458.44%
3Y Avg
-317.77%
5Y Avg
-317.77%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| RenovoRx, Inc. (RNXT) | $62.62M | -1113.80% | -770.58% | N/A | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $62.78M | -0.14% | -3.20% | -62.68% | -125.61% |
| InterCure Ltd. (INCR)vs › | $63.02M | 8.84% | -6.43% | -1.20% | -7.11% |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.78M | -11538.23% | -6406.80% | -3544.47% | -2835.62% |
| Alps Group Inc (ALPS)vs › | $64.18M | -46.36% | -44.45% | -49.00% | -37.18% |
| Fractyl Health, Inc. (GUTS)vs › | $60.42M | -99843.01% | -70984.01% | -70984.01% | -70984.01% |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.02M | -753.96% | -753.96% | -753.96% | -753.96% |
| XBiotech Inc. (XBIT)vs › | $65.85M | -794.91% | -458.44% | -317.77% | -317.77% |
| Cingulate Inc. (CING)vs › | $65.86M | N/A | N/A | N/A | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $65.87M | -334.74% | -191.68% | -191.68% | -191.68% |
Gross Margin
70.9%
EBITDA Margin
-1113.8%
Operating Margin
-1114.0%
Net Margin
-621.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -352.15% |
| 2026-03-31 | -615.99% |
| 2025-12-31 | -1479.83% |
| 2025-06-30 | -634.36% |
| 2025-03-31 | -1578.17% |
| 2024-12-31 | 0.00% |
